There are some new potential biomarkers of cancer in myositis: the IgG2 isotype of anti-TIF1γ helps to identify the risk of mortality in anti-TIF1γ+ patients (31); soluble programmed death ligand 1 (sPD-L1), combined with anti-TIF1γ antibodies, yielded greater specificity and positive predictive value in diagnosing cancer, reaching values of 95% and 70%, respectively (32). This evidence concerns the gene SPDL1 and myositis disease.